
Nasal provocation of patients with allergic rhinitis and the hypothalamic-pituitary-adrenal axis

Demetrios Kalogeromitros, MD, PhD*; E. Katerini I. Syrigou, MD*; Michael Makris, MD*; Duraisamy Kempuraj, PhD†; Nikolaos G. Stavrianeas, MD, PhD*; Magdalini Vasiadi, BS‡; and Theoharis C. Theoharides, MS, MPhil, PhD, MD*†‡

Background: Allergic rhinitis is a common problem involving activation of nasal mast cells and irritability. The hypothalamic-pituitary-adrenal (HPA) axis is stimulated in cases of emotional or environmental stress, and mast cells have been implicated in stress-induced immune responses.

Objective: To investigate whether intranasal challenge of patients allergic to a single antigen would stimulate the HPA axis.

Methods: Plasma corticotropin and cortisol levels were measured 20, 40, 60, 80, 100, and 120 minutes after intranasal antigen administration in healthy volunteers (n = 3) and in patients with rhinitis who are allergic to *Parietaria* (n = 10).

Results: Mean \pm SD corticotropin levels were 24.43 ± 14.38 pg/mL in patients compared with 8.83 ± 5.02 pg/mL in controls, and this increase was statistically significant ($P = .049$). Patient cortisol levels also increased to a mean \pm SD of 8.87 ± 4.90 pg/mL (at 40 minutes) compared with 4.36 ± 1.72 pg/mL in controls ($P = .11$ due to 1 outlier). Compared with individual patient prechallenge levels, corticotropin levels increased in 7 patients and cortisol levels increased in 5 at 40 minutes.

Conclusion: These results suggest that allergic rhinitis may activate the HPA axis. A larger study with additional controls is required for definitive conclusions.

Ann Allergy Asthma Immunol. 2007;98:269–273.

INTRODUCTION

Allergic rhinitis is a chronic condition that affects 10% to 25% of the population,¹ with a significant impact on patients' lives, especially the quality of sleep.² The allergic patient is characterized by emotional instability, sometimes called the "allergic irritability syndrome,"³ and increased anxiety.^{4,5} Stress has also been shown to increase morbidity in children with asthma.⁶ Allergic rhinitis involves the activation of nasal mast cells,⁷ which are now considered important in immunity,⁸ especially on mucosal surfaces.⁹ Mast cells are also implicated in nervous-immune interactions¹⁰ and in the pathogenesis of inflammatory conditions worsened by stress.¹¹ We hypothesized that nasal mast cell stimulation by allergens may release molecules that could activate the hypothalamic-pituitary-adrenal (HPA) axis. These molecules could include corticotropin-releasing hormone (CRH),¹² histamine,¹³ inter-

leukin 1 (IL-1),¹⁴ IL-6,¹⁵ and prostaglandins.^{16,17} The HPA axis may then become overactive, leading to unwanted behavioral and physical consequences.

PATIENTS AND METHODS

Individuals with a history of rhinitis to *Parietaria officinalis* pollen were enrolled on the basis of the following inclusion criteria: (1) aged 18 to 60 years and (2) a positive history of allergic rhinitis during the latest pollen season confirmed by either a positive skin prick test reaction (wheal diameter >3 mm) or a positive radioallergen sorbent test result for specific serum IgE (>0.70 kU/L) for *Parietaria* pollen (UniCAP; Pharmacia Diagnostics, Uppsala, Sweden). Exclusion criteria were (1) uncompensated asthma (peak expiratory flow rate $<80\%$ of the reference value); (2) symptoms of allergic, viral, or infectious rhinitis within 2 weeks of the nasal provocation test (NPT); (3) symptoms of allergic rhinitis during the study; (4) major nasal septum deviation or polyposis; (5) use of medications that might affect the test variables during the week before study onset (oral or topical antihistamines, corticosteroids or antidepressants with antiallergic properties, and antihypertensive agents); (6) pregnancy or the absence of adequate contraception; and (7) a nonspecific nasal reaction (nasal reaction threshold reached with diluent alone at inclusion). Three nonatopic individuals who fulfilled the criteria were included in this study as controls. The NPTs were performed outside the *Parietaria* pollen season to exclude concomitant natural exposure to the allergen. The Attikon Hospital Human Subject Review Board approved the re-

* Allergy Clinical Research Center, Allergy Section, Attikon Hospital, University of Athens Medical School, Athens, Greece.

† Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Tufts–New England Medical Center, Boston, Massachusetts.

‡ Departments of Biochemistry, Internal Medicine, and Psychiatry, Tufts University School of Medicine, Tufts–New England Medical Center, Boston, Massachusetts.

This work was funded in part by Theta Biomedical Consulting and Development Co Inc (Brookline, MA).

Received for publication October 5, 2006.

Received in revised form December 8, 2006.

Accepted for publication December 16, 2006.

search protocol, and written informed consent was obtained from each volunteer.

The NPT started with the determination of nonspecific reactivity.¹⁸ Two actuations (mean \pm SD, 0.12 \pm 0.01 mL) from nasal spray bottles containing challenge material were nebulized into each nostril of all the participants at end inspiration. Five and 10 minutes after the challenge, the number of sneezes was recorded, and the subjective symptoms of nasal itchiness and nasal congestion were evaluated by means of a visual analog scale (0 = absent and 10 = severe). Peak nasal inspiratory flow (PNIF) was also determined at 5 and 10 minutes. This sequence was repeated at each allergen concentration every 20 minutes. The same batch of standardized allergen (ALK-Abello, Copenhagen, Denmark) was used throughout the study, and serial dilutions (2, 4, and 8 BU/mL) were prepared in phosphate-buffered saline solution immediately before NPT.

The nasal reaction threshold (combined threshold) was reached when a decrease in PNIF of 40% or greater of baseline values was recorded 5 or 10 minutes after the challenge and at least 1 of the 2 following clinical criteria were fulfilled: (1) 5 or more sneezes and (2) total score greater than 10 on the visual analog scale of nasal itchiness and nasal congestion at 5 or 10 minutes.¹⁸ Peak nasal inspiratory flow was measured using a flow meter (Jaeger, Wurzburg, Germany). The best of 3 consecutive measurements of PNIF was registered.

Before the protocol onset and 0, 20, 40, 60, 80, 100, and 120 minutes after reaching the nasal reaction threshold (a positive NPT reaction) or an equivalent time in control subjects, blood samples were collected via an intravenous catheter and were centrifuged, and the plasma was stored at -20°C until assay. These time points were chosen because they are typically used during the HPA challenge test. Patients were not followed up past 120 minutes to determine when cortisol levels recovered to prechallenge levels. Plasma corticotropin (100B Dyno Test; Brahms, Berlin, Germany) and cortisol (EU; Diasorin, Stillwater, MN) concentrations were determined by means of radioimmunoassay for each time point. Six patients were excluded because of recent medication use and 3 more owing to a nonspecific nasal reaction at the inclusion NPT. Ten patients (5 men and 5 women) finally completed the whole study and were included in the analysis; their mean \pm SD age was 49.7 \pm 8.5 years (range, 35–59 years). Three controls (1 man and 2 women) with a mean \pm SD age of 32.3 \pm 7.5 years (range, 28–41 years) made up the control group. All the participants were brought into the clinic at approximately 10 AM on a day outside the *Parietaria* pollen season to control for diurnal cortisol and corticotropin variations and environmental exposure.

The mean \pm SD corticotropin and cortisol levels were compared with those of controls at different time points after challenge, and individual values at different time points were also compared with time 0 for each participant using the

nonparametric Mann-Whitney *U* test. Significance was set at $P < .05$.

RESULTS

Results are presented as scattergrams to show the individual participant variability (Fig 1A and C) and with the actual values connected in line drawings to show the pattern of change for each individual patient (Fig 1B and D). There was considerable variability among patients that may be due to their degree of sensitivity to the allergen or other inherent factors.

The corticotropin levels increased in most patients (7 of 10) compared with prechallenge levels. The mean \pm SD corticotropin levels after challenge were 24.43 \pm 14.38 pg/mL at 40 minutes and 21.75 \pm 8.21 pg/mL at 60 minutes; these were significantly higher compared with those of control subjects at 40 minutes (8.83 \pm 5.02 pg/mL; $P = .049$) and 60 minutes (10.23 \pm 3.56 pg/mL; $P = .04$) (Fig 1A and B).

Mean \pm SD plasma cortisol levels also increased in patients (8.87 \pm 4.90 and 8.57 \pm 3.38 pg/mL at 40 and 60 minutes, respectively) compared with controls (4.36 \pm 1.72 and 4.66 \pm 1.85 pg/mL at 40 and 60 minutes, respectively) (Fig 1C and D), but this difference was not significant owing to 1 outlier value ($P = .01$). However, compared with the individual patient prechallenge levels at 40 minutes, cortisol levels were increased in 5 patients, remained the same in 1, and decreased in 4. The corticotropin and cortisol levels of controls were unaffected (Fig 1).

DISCUSSION

These results suggest that intranasal challenge of patients allergic to a single antigen may stimulate the HPA axis. However, no definitive conclusion can be made because the effect recorded was weak and variable; furthermore, the effect of priming with repeated antigen exposure on the HPA axis is not known. Other possibilities must also be excluded: (1) actual values must be recorded for the effect of the pollen extract diluent, although preliminary results showed no effect; (2) this study should be repeated in the evening when endogenous cortisol levels are low because challenge studies performed in the morning, when cortisol levels are higher do not occur as readily¹⁹; and (3) a possible effect on the HPA axis of the stress of the nasal occlusion should be excluded, but this is difficult to control for. Nasal occlusion could be excluded by means of intranasal histamine challenge in controls and patients, but histamine has also been shown to stimulate the HPA axis.¹³

The effect we observed could be due to molecules released in the nose that reach the median eminence and the pituitary through the cribriform plexus.²⁰ For example, histamine¹³ and prostaglandins^{16,17} are synthesized by mast cells and can activate the HPA axis; IL-6 is also synthesized by mast cells and is an independent activator of the HPA axis.¹⁵ Furthermore, human mast cells also release IL-6 in response to IL-1,²¹ and IL-1 can independently stimulate the HPA axis.¹⁴




Figure 1. Plasma corticotropin (A and B) and cortisol (C and D) levels of controls (C) ($n = 3$) and patients with allergic rhinitis *Parietaria* (P) ($n = 10$) challenged with this specific antigen. Results are presented as scattergrams (A and C), where the means of the control and patient groups are shown as short horizontal bars, and with the time points connected (B and D) to appreciate the pattern of change for each individual patient. The values for the controls were arbitrarily increased by 3 points on the x -axis to separate them from the patient values for easier readability. Blood samples were collected before any challenge (time 0) and after positive specific nasal provocation tests with increasing amounts of *Parietaria* (2, 4, and 8 BU/mL) every 20 minutes (up to 120 minutes). Plasma corticotropin and cortisol levels were measured blindly.

Human mast cells also release CRH on allergic stimulation.¹² Once inflammation develops, CRH could also be synthesized by infiltrating lymphocytes,²² although this is likely to be a delayed response. This late phase may also involve cytokines/chemokines released from basophils and eosinophils, both important in allergic inflammation. Brain and nasal mast cells could then be further activated by CRH²³ or somatostatin²⁴ released from the hypothalamus. Measurement of IL-6 or

CRH in nasal fluid after antigen challenge would confirm mast cell mediator involvement.

We had first proposed that brain mast cells may act as an “immune gate to the brain.”²⁵ We later showed that mast cells could be activated by acute stress²⁶ and increase the permeability of the blood-brain barrier through activation of specific CRH receptors.²⁷ Intracerebral administration of the mast cell secretagogue compound 48/80 increased HPA axis

activity in rats,²⁸ with accompanying corticosterone secretion.²⁹ Intracerebral activation of brain mast cells in dogs sensitized to ovalbumin also led to HPA axis activation.³⁰ However, in both these cases, the trigger had to be given intraventricularly, clearly not a physiologic state. In a study of rats immunized to hemocyanin, intravenous challenge with large amounts of antigen induced a small increase in the corticosterone level.³¹ However, anaphylactic reactions may release sufficient systemic amounts of histamine and cytokines to either reach the pituitary or cross the blood-brain barrier and activate the HPA axis,³² possibly in an effort to minimize this response through the secretion of adrenal corticosteroids.

The ability of nasal mast cells to activate the HPA axis may help explain the increased association of allergic rhinitis and anxiety.^{4,6} It will be interesting to investigate whether nonallergic triggers, such as cigarette smoke, could also activate the HPA axis in nonallergic individuals. Mast cells may act as “sensors” of environmental stress,²³ possibly providing an explanation for the “irritable allergic patient” concept and the popular saying “we smell danger.” In general, these results support the diverse roles of mast cells.³³

ACKNOWLEDGMENTS

We thank Biocheck Int SA, Medical Diagnostic Center, Athens, Greece, for the corticotropin and cortisol measurements and Jessica Christian for her patience and word processing skills.

REFERENCES

1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. *J Allergy Clin Immunol*. 2001;108:S2–S8.
2. Leger D, Annesi-Maesano I, Carat F, et al. Allergic rhinitis and its consequences on quality of sleep: an unexplored area. *Arch Intern Med*. 2006;166:1744–1748.
3. Klein GL, Ziering RW, Girsh LS, Miller MF. The allergic irritability syndrome: four case reports and a position statement from the Neuroallergy Committee of the American College of Allergy. *Ann Allergy*. 1985;55:22–24.
4. Hashizume H, Takigawa M. Anxiety in allergy and atopic dermatitis. *Curr Opin Allergy Clin Immunol*. 2006;6:335–339.
5. Annesi-Maesano I, Beyer A, Marmouz F, Mathelier-Fusade P, Vervloet D, Bauchau V. Do patients with skin allergies have higher levels of anxiety than patients with allergic respiratory diseases? results of a large-scale cross-sectional study in a French population. *Br J Dermatol*. 2006;154:1128–1136.
6. Chen E, Fisher EB, Bacharier LB, Strunk RC. Socioeconomic status, stress, and immune markers in adolescents with asthma. *Psychosom Med*. 2003;65:984–992.
7. Pawankar R. Mast cells in allergic airway disease and chronic rhinosinusitis. *Chem Immunol Allergy*. 2005;87:111–129.
8. Galli SJ, Kalesnikoff J, Grimaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. *Annu Rev Immunol*. 2005;23:749–786.
9. Vliagoftis H, Befus AD. Mast cells at mucosal frontiers. *Curr Mol Med*. 2005;5:573–589.
10. Williams RM, Bienenstock J, Stead RH. Mast cells: the neuro-immune connection. *Chem Immunol*. 1995;61:208–235.
11. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol*. 2004;146:1–12.
12. Kempuraj D, Papadopoulou NG, Lytinas M, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. *Endocrinology*. 2004;145:43–48.
13. Bugajski AJ, Koprowska B, Thor P, Glod R, Bugajski J. Involvement of nitric oxide in central histaminergic stimulation of the hypothalamic-pituitary-adrenal axis. *J Physiol Pharmacol*. 2000;51:907–915.
14. Tsagarakis S, Gillies G, Rees LH, Besser M, Grossman A. Interleukin-1 directly stimulates the release of corticotrophin releasing factor from rat hypothalamus. *Neuroendocrinology*. 1989;49:98–101.
15. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. *J Clin Endocrinol Metab*. 1993;77:1690–1694.
16. Caldwell JE, Heiss SG, Mermall V, Cooper JA. Effects of CapZ, an actin capping protein of muscle, on the polymerization of actin. *Biochemistry*. 1989;28:8506–8514.
17. Bugajski AJ, Gadek-Michalska A, Bugajski J. The involvement of nitric oxide and prostaglandins in the cholinergic stimulation of hypothalamic-pituitary-adrenal response during crowding stress. *J Physiol Pharmacol*. 2006;57:463–477.
18. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. *Am Rev Respir Dis*. 1983;128:597–602.
19. Schleimer RP. Interactions between the hypothalamic-pituitary-adrenal axis and allergic inflammation. *J Allergy Clin Immunol*. 2000;106:S270–S274.
20. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. *Physiol Rev*. 1999;79:1–71.
21. Kandere-Grzybowska K, Letourneau R, Boucher W, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. *J Immunol*. 2003;171:4830–4836.
22. Karalis K, Louis JM, Bae D, Hilderbrand H, Majzoub JA. CRH and the immune system. *J Neuroimmunol*. 1997;72:131–136.
23. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. *Trends Pharmacol Sci*. 2004;25:563–568.
24. Theoharides TC, Douglas WW. Somatostatin induces histamine secretion from rat peritoneal mast cells. *Endocrinology*. 1978;102:1637–1640.
25. Theoharides TC. Mast cells: the immune gate to the brain. *Life Sci*. 1990;46:607–617.
26. Esposito P, Gheorghe D, Kandere K, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. *Brain Res*. 2001;888:117–127.
27. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol*. 2005;174:7665–7675.
28. Gadek-Michalska A, Chlap Z, Turon M, Bugajski J, Fogel WA. The intracerebroventricularly administered mast cells degranulator compound 48/80 increases the pituitary-adrenocortical activity in rats. *Agents Actions*. 1991;32:203–208.

-
29. Bugajski AJ, Chlap Z, Gadek-Michalska A, Borycz J, Bugajski J. Degranulation and decrease in histamine levels of thalamic mast cells coincides with corticosterone secretion induced by compound 48/80. *Inflamm Res*. 1995;44(suppl 1):S50–S51.
30. Matsumoto I, Inoue Y, Shimada T, Aikawa T. Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs. *J Exp Med*. 2001;194:71–78.
31. Stenzel-Poore M, Vale WW, Rivier C. Relationship between antigen-induced immune stimulation and activation of the hypothalamic-pituitary-adrenal axis in the rat. *Endocrinology*. 1993;132:1313–1318.
32. Foldes A, Nemethy Z, Szalay O, Kovacs KJ. Anaphylactoid reactions activate hypothalamo-pituitary-adrenocortical axis: comparison with endotoxic reactions. *Brain Res Bull*. 2000;52:573–579.
33. Gurish MF, Austen KF. The diverse roles of mast cells. *J Exp Med*. 2001;194:1–6.

Requests for reprints should be addressed to:
Theoharis C. Theoharides, MD, PhD, MS, MPhil
Department of Pharmacology and Experimental Therapeutics
Tufts University School of Medicine
136 Harrison Ave
Boston, MA 02111
E-mail: theoharis.theoharides@tufts.edu